EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.

Item

http://www.wikidata.org/entity/Q49874595

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

EANM guideline for radionuclid ...... ion-resistant prostate cancer.

@en

EANM guideline for radionuclid ...... ion-resistant prostate cancer.

@nl

type

Item

label

EANM guideline for radionuclid ...... ion-resistant prostate cancer.

@en

EANM guideline for radionuclid ...... ion-resistant prostate cancer.

@nl

prefLabel

EANM guideline for radionuclid ...... ion-resistant prostate cancer.

@en

EANM guideline for radionuclid ...... ion-resistant prostate cancer.

@nl

P1476

EANM guideline for radionuclid ...... tion-resistant prostate cancer

@en

P2093

Alexander Becherer

http://www.w3.org/2001/XMLSchema#string

Alexander Heinzel

http://www.w3.org/2001/XMLSchema#string

Andreas Bockisch

http://www.w3.org/2001/XMLSchema#string

Bernd J Krause

http://www.w3.org/2001/XMLSchema#string

Eva Fricke

http://www.w3.org/2001/XMLSchema#string

Lilli Geworski

http://www.w3.org/2001/XMLSchema#string

Lisa Bodei

http://www.w3.org/2001/XMLSchema#string

Michael Andreeff

http://www.w3.org/2001/XMLSchema#string

Michael Gabriel

http://www.w3.org/2001/XMLSchema#string

Thomas Krause

http://www.w3.org/2001/XMLSchema#string

P2860

Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.

Alpha emitter radium-223 and survival in metastatic prostate cancer

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases.

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 A

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)

P2888

s00259-017-3900-4

P304

824-845

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-017-3900-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Markus Mitterhauser

Roberto Delgado- Bolton

Daria Handkiewicz-Junak

P577

2017-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29234845

http://www.w3.org/2001/XMLSchema#string